Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Operating Leases (2020 - 2026)

Immuneering's Operating Leases history spans 7 years, with the latest figure at $3.7 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 8.63% to $3.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.7 million, a 8.63% decrease, with the full-year FY2025 number at $3.4 million, down 10.38% from a year prior.
  • Operating Leases came in at $3.7 million for Q1 2026, up from $3.4 million in the prior quarter.
  • The five-year high for Operating Leases was $4.7 million in Q1 2023, with the low at $3.4 million in Q4 2025.
  • Historically, Operating Leases has averaged $4.2 million across 5 years, with a median of $4.3 million in 2023.
  • Biggest five-year swings in Operating Leases: soared 842.53% in 2022 and later fell 15.73% in 2025.
  • Year by year, Operating Leases stood at $4.5 million in 2022, then dropped by 6.72% to $4.2 million in 2023, then decreased by 8.13% to $3.8 million in 2024, then fell by 10.38% to $3.4 million in 2025, then grew by 8.84% to $3.7 million in 2026.
  • Business Quant data shows Operating Leases for IMRX at $3.7 million in Q1 2026, $3.4 million in Q4 2025, and $3.9 million in Q3 2025.